Jodie Ingles

List of Publications by Year
in descending order

168 papers	8,114 citations	66234 42 h-index	56606 83 g-index
182 all docs	182 docs citations	182 times ranked	7159 citing authors

#	Article	IF	Citations
1	New Perspectives on the Prevalence ofÂHypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2015, 65, 1249-1254.	1.2	918
2	A Prospective Study of Sudden Cardiac Death among Children and Young Adults. New England Journal of Medicine, 2016, 374, 2441-2452.	13.9	619
3	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.3	494
4	Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. Journal of Medical Genetics, 2005, 42, e59-e59.	1.5	327
5	Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGenâ€™s Inherited Cardiomyopathy Expert Panel. Genetics in Medicine, 2018, 20, 351-359.	1.1	283
6	Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circulation Genomic and Precision Medicine, 2019, 12, e002460.	1.6	267
7	Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. European Heart Journal, 2015, 36, 1290-1296.	1.0	217
8	Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation, 2021, 144, 7-19.	1.6	213
9	Mutations in Alpha-Actinin-2 Cause Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2010, 55, 1127-1135.	1.2	170
10	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Heart Rhythm, 2021, 18, e1-e50.	0.3	151
11	Nonfamilial Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	141
12	Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 419-429.	1.2	138
13	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.3	135
14	A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Circulation, 2020, 142, 217-229.	1.6	129
15	A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart, 2012, 98, 625-630.	1.2	119
16	Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genetics in Medicine, 2013, 15, 972-977.	1.1	110
17	Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction. Circulation, 2020, 141, 1371-1383.	1.6	108
18	The emerging role of the cardiac genetic counselor. Heart Rhythm, 2011, 8, 1958-1962.	0.3	104

#	Article	IF	Citations
19	Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy. Genetics in Medicine, 2008, 10, 117-120.	1.1	102
20	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. European Heart Journal, 2019, 40, 2953-2961.	1.0	96
21	Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005371.	1.6	96
22	Multiple Gene Variants in Hypertrophic Cardiomyopathy in the Era of Next-Generation Sequencing. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	86
23	Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. Genetics in Medicine, 2014, 16, 286-293.	1.1	83
24	Sudden cardiac death in the young: a clinical genetic approach. Internal Medicine Journal, 2007, 37, 32-37.	0.5	82
25	Psychological wellbeing and posttraumatic stress associated with implantable cardioverter defibrillator therapy in young adults with genetic heart disease. International Journal of Cardiology, 2013, 168, 3779-3784.	0.8	82
26	Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. American Journal of Cardiology, 2004, 93, 1192-1194.	0.7	77
27	Role of Genetic Testing in Inherited Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1153.	3.0	75
28	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 1988-1996.	1.0	69
29	Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2007, 43, 337-343.	0.9	68
30	Natural history of genotype positiveâ€“phenotype negative patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2011, 152, 258-259.	0.8	61
31	A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2016, 13, 1652-1660.	0.3	60
32	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology, 2020, 5, 83.	3.0	60
33	Posttraumatic Stress and Prolonged Grief After the Sudden Cardiac Death of a Young Relative. JAMA Internal Medicine, 2016, 176, 402.	2.6	59
34	Guidelines for Genetic Testing of Inherited Cardiac Disorders. Heart Lung and Circulation, 2011, 20, 681-687.	0.2	58
35	Application of Genetic Testing in Hypertrophic Cardiomyopathy for Preclinical Disease Detection. Circulation: Cardiovascular Genetics, 2015, 8, 852-859.	5.1	57
36	Conveying a probabilistic genetic test result to families with an inherited heart disease. Heart Rhythm, 2014, 11, 1073-1078.	0.3	54

#	Article	IF	Citations
37	Interdisciplinary psychosocial care for families with inherited cardiovascular diseases. Trends in Cardiovascular Medicine, 2016, 26, 647-653.	2.3	52
38	Genome sequencing as a first-line genetic test in familial dilated cardiomyopathy. Genetics in Medicine, 2019, 21, 650-662.	1.1	52
39	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. Heart Lung and Circulation, 2021, 30, 324-349.	0.2	51
40	Sex hormone receptor gene variation associated with phenotype in male hypertrophic cardiomyopathy patients. Journal of Molecular and Cellular Cardiology, 2008, 45, 217-222.	0.9	49
41	Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers. Open Heart, 2016, 3, e000484.	0.9	48
42	Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 396-405.	1.6	47
43	Molecular autopsy in victims of inherited arrhythmias. Journal of Arrhythmia, 2016, 32, 359-365.	0.5	46
44	Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences. Journal of Molecular and Cellular Cardiology, 2005, 38, 387-393.	0.9	44
45	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms ofCASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2020, 142, 932-947.	1.6	44
46	Health status of cardiac genetic disease patients and their at-risk relatives. International Journal of Cardiology, 2013, 165, 448-453.	0.8	43
47	Factors influencing uptake of familial long QT syndrome genetic testing. American Journal of Medical Genetics, Part A, 2016, 170, 418-425.	0.7	43
48	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3932-3944.	1.0	43
49	Postmortem molecular analysis of KCNQ1 and SCN5A genes in sudden unexplained death in young Australians. International Journal of Cardiology, 2008, 127, 138-141.	0.8	42
50	Poor psychological wellbeing particularly in mothers following sudden cardiac death in the young. European Journal of Cardiovascular Nursing, 2013, 12, 484-491.	0.4	40
51	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. Genetics in Medicine, 2021, 23, 69-79.	1.1	39
52	Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dual-chamber pacing. American Journal of Cardiology, 2005, 95, 991-993.	0.7	38
53	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003062.	1.6	38
54	Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy. International Journal of Cardiology, 2004, 96, 157-163.	0.8	37

#	Article	IF	Citations
55	Prolongation of the QTc Interval Predicts Appropriate Implantable Cardioverter-Defibrillator Therapies in Hypertrophic Cardiomyopathy. JACC: Heart Failure, 2013, 1, 149-155.	1.9	37
56	The value of cardiac genetic testing. Trends in Cardiovascular Medicine, 2014, 24, 217-224.	2.3	37
57	â€œConcealed cardiomyopathyâ€•as a cause of previously unexplained sudden cardiac arrest. International Journal of Cardiology, 2021, 324, 96-101.	0.8	37
58	Tweeting Our Way to Cardiovascular Health. Journal of the American College of Cardiology, 2013, 61, 1657-1658.	1.2	35
59	Cardiovascular Effects of Energy Drinks in Familial Long QT Syndrome: A Randomized Cross-Over Study. International Journal of Cardiology, 2017, 231, 150-154.	0.8	35
60	Concealed Arrhythmogenic Right Ventricular Cardiomyopathy in Sudden Unexplained Cardiac Death Events. Circulation Genomic and Precision Medicine, 2018, 11, e002355.	1.6	34
61	Genetic Testing in Inherited Heart Diseases. Heart Lung and Circulation, 2020, 29, 505-511.	0.2	34
62	Key Value of RNA Analysis of MYBPC3 Splice-Site Variants in Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2019, 12, e002368.	1.6	31
63	Attitudes, knowledge and consequences of uncertain genetic findings in hypertrophic cardiomyopathy. European Journal of Human Genetics, 2017, 25, 809-815.	1.4	30
64	Communication of genetic information to families with inherited rhythm disorders. Heart Rhythm, 2018, 15, 780-786.	0.3	30
65	External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2022, 29, 678-686.	0.8	30
66	Perceptions of genetic variant reclassification in patients with inherited cardiac disease. European Journal of Human Genetics, 2019, 27, 1134-1142.	1.4	29
67	Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment. Current Heart Failure Reports, 2021, 18, 264-273.	1.3	28
68	Genetic architecture of left ventricular noncompaction in adults. Human Genome Variation, 2020, 7, 33.	0.4	27
69	Genetic testing for inherited heart diseases: longitudinal impact on health-related quality of life. Genetics in Medicine, 2012, 14, 749-752.	1.1	26
70	Exome sequencingâ€“based molecular autopsy of formalin-fixed paraffin-embedded tissue after sudden death. Genetics in Medicine, 2017, 19, 1127-1133.	1.1	26
71	Social determinants of health in the setting of hypertrophic cardiomyopathy. International Journal of Cardiology, 2015, 184, 743-749.	0.8	25
72	Temporal Trends in Sudden Cardiac Death From 1997 to 2010: A Data Linkage Study. Heart Lung and Circulation, 2017, 26, 808-816.	0.2	23

#	Article	IF	Citations
73	Relations between right ventricular morphology and clinical, electrical and genetic parameters in Brugada Syndrome. PLoS ONE, 2018, 13, e0195594.	1.1	23
74	Psychosocial Implications of Living with Catecholaminergic Polymorphic Ventricular Tachycardia in Adulthood. Journal of Genetic Counseling, 2018, 27, 549-557.	0.9	21
75	Delay to diagnosis amongst patients with catecholaminergic polymorphic ventricular tachycardia. International Journal of Cardiology, 2014, 176, 1402-1404.	0.8	20
76	Psychological adaptation to molecular autopsy findings following sudden cardiac death in the young. Genetics in Medicine, 2019, 21, 1452-1456.	1.1	19
77	Discordant clinical features of identical hypertrophic cardiomyopathy twins. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	19
78	The Australian Genetic Heart Disease Registry. International Journal of Cardiology, 2013, 168, e127-e128.	0.8	18
79	Burden of Recurrent and Ancestral Mutations in Families With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	18
80	Genetic Testing for Cardiomyopathies in Clinical Practice. Heart Failure Clinics, 2018, 14, 129-137.	1.0	18
81	Implantable cardioverterâ€“defibrillator therapy in Australia, 2002â€“2015. Medical Journal of Australia, 2018, 209, 123-129.	0.8	18
82	The End Unexplained Cardiac Death (EndUCD) Registry for Young Australian Sudden Cardiac Arrest. Heart Lung and Circulation, 2021, 30, 714-720.	0.2	18
83	Transcriptome Sequencing of Patients With Hypertrophic Cardiomyopathy Reveals Novel Splice-Altering Variants in MYBPC3. Circulation Genomic and Precision Medicine, 2021, 14, e003202.	1.6	18
84	Needs analysis of parents following sudden cardiac death in the young. Open Heart, 2020, 7, e001120.	0.9	17
85	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Journal of Arrhythmia, 2021, 37, 481-534.	0.5	17
86	Minding the Genes: a Multidisciplinary Approach towards Genetic Assessment of Cardiovascular Disease. Journal of Genetic Counseling, 2017, 26, 224-231.	0.9	16
87	Precision Medicine in Cardiovascular Disease: Genetics and Impact on Phenotypes. Journal of the American College of Cardiology, 2021, 77, 2517-2530.	1.2	16
88	Challenges of Exercise Recommendations and Sports Participation in Genetic Heart Disease Patients. Circulation: Cardiovascular Genetics, 2015, 8, 178-186.	5.1	15
89	Psychosocial care and cardiac genetic counseling following sudden cardiac death in the young. Progress in Pediatric Cardiology, 2017, 45, 31-36.	0.2	15
90	Lack of genotype-phenotype correlation in Brugada Syndrome and Sudden Arrhythmic Death Syndrome families with reported pathogenic SCN1B variants. Heart Rhythm, 2018, 15, 1051-1057.	0.3	15

#	Article	IF	Citations
91	Molecular Diagnostics of Cardiomyopathies. Circulation: Cardiovascular Genetics, 2011, 4, 103-104.	5.1	14
92	Epidemiology and clinical characteristics of atrial fibrillation in patients with inherited heart diseases. Journal of Cardiovascular Electrophysiology, 2020, 31, 465-473.	0.8	14
93	Sex Disparities in Sudden Cardiac Death. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009834.	2.1	14
94	Whole genome sequencing delineates regulatory, copy number, and cryptic splice variants in early onset cardiomyopathy. Npj Genomic Medicine, 2022, 7, 18.	1.7	14
95	Establishment of an Australian National Genetic Heart Disease Registry. Heart Lung and Circulation, 2008, 17, 463-467.	0.2	13
96	Psychosocial Impact of a Positive Gene Result for Asymptomatic Relatives at Risk of Hypertrophic Cardiomyopathy. Journal of Genetic Counseling, 2018, 27, 1040-1048.	0.9	13
97	A balanced translocation disrupting SCN5A in a family with Brugada syndrome and sudden cardiac death. Heart Rhythm, 2019, 16, 231-238.	0.3	13
98	Characterization of clinically relevant copy-number variants from exomes of patients with inherited heart disease and unexplained sudden cardiac death. Genetics in Medicine, 2021, 23, 86-93.	1.1	13
99	The genetic architecture of Plakophilin 2 cardiomyopathy. Genetics in Medicine, 2021, 23, 1961-1968.	1.1	13
100	Rarity and phenotypic heterogeneity provide challenges in the diagnosis of Andersenâ€“Tawil syndrome: Two cases presenting with ECGs mimicking catecholaminergic polymorphic ventricular tachycardia (CPVT). International Journal of Cardiology, 2015, 201, 473-475.	0.8	12
101	A Control Theory-Based Pilot Intervention toIncrease Physical Activity in Patients WithHypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 866-871.	0.7	12
102	Psychological Issues in Managing Families with Inherited Cardiovascular Diseases. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036558.	2.9	12
103	Homozygous mutation in the cardiac troponin I gene: Clinical heterogeneity in hypertrophic cardiomyopathy. International Journal of Cardiology, 2013, 168, 1530-1531.	0.8	11
104	Time to Rethink the Genetic Architecture of Long QT Syndrome. Circulation, 2020, 141, 440-443.	1.6	11
105	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Genetics in Medicine, 2021, 23, 1281-1287.	1.1	11
106	Genetic variants associated with inherited cardiovascular disorders among 13,131 asymptomatic older adults of European descent. Npj Genomic Medicine, 2021, 6, 51.	1.7	11
107	Hypertrophic Cardiomyopathy: Genetic Testing and Risk Stratification. Current Cardiology Reports, 2021, 23, 9.	1.3	11
108	Pathogenicity of Hypertrophic Cardiomyopathy Variants. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	10

#	Article	IF	Citations
109	Impact of the implantable cardioverter defibrillator on confidence to undertake physical activity in inherited heart disease: A cross-sectional study. European Journal of Cardiovascular Nursing, 2017, 16, 742-752.	0.4	10
110	Revisiting Genome Sequencing Data in Light of Novel Disease Gene Associations. Journal of the American College of Cardiology, 2019, 73, 1365-1366.	1.2	10
111	Revisiting the Diagnostic Yield of Hypertrophic Cardiomyopathy Genetic Testing. Circulation Genomic and Precision Medicine, 2020, 13, e002930.	1.6	10
112	Clinical Profile and Health Disparities in a Multiethnic Cohort of Patients With Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e007537.	1.6	10
113	Determining pathogenicity in cardiac genetic testing: Filling in the blank spaces. Trends in Cardiovascular Medicine, 2015, 25, 653-654.	2.3	9
114	Exome sequencing identifies a novel mutation in the MYH6 gene in a family with early-onset sinus node dysfunction, ventricular arrhythmias, and cardiac arrest. HeartRhythm Case Reports, 2015, 1, 141-145.	0.2	9
115	Clinical and genetic features of Australian families with long QT syndrome: A registryâ€based study. Journal of Arrhythmia, 2016, 32, 456-461.	0.5	9
116	Rare desmin variant causing penetrant life-threatening arrhythmic cardiomyopathy. HeartRhythm Case Reports, 2018, 4, 318-323.	0.2	9
117	Decision-making and experiences of preimplantation genetic diagnosis in inherited heart diseases: a qualitative study. European Journal of Human Genetics, 2022, 30, 187-193.	1.4	9
118	Arrhythmia in Cardiomyopathy: Sex and Gender Differences. Current Heart Failure Reports, 2021, 18, 274-283.	1.3	9
119	Development of a communication aid for explaining hypertrophic cardiomyopathy genetic test results. Pilot and Feasibility Studies, 2017, 3, 53.	0.5	8
120	Global approaches to cardiogenetic evaluation after sudden cardiac death in the young: A survey among health care professionals. Heart Rhythm, 2021, 18, 1637-1644.	0.3	8
121	Predictors and outcomes of in-hospital referrals for forensic investigation after young sudden cardiac death. Heart Rhythm, 2022, 19, 937-944.	0.3	8
122	How Patient Perceptions Shape Responses and Outcomes in Inherited Cardiac Conditions. Heart Lung and Circulation, 2020, 29, 641-652.	0.2	7
123	LAMP2 shines a light on cardiomyopathy in an athlete. HeartRhythm Case Reports, 2017, 3, 172-176.	0.2	6
124	A prospective longitudinal study of health-related quality of life and psychological wellbeing after an implantable cardioverter-defibrillator in patients with genetic heart diseases. Heart Rhythm O2, 2022, 3, 143-151.	0.6	6
125	Expanding the Genetic Spectrum of Hypertrophic Cardiomyopathy: X Marks the Spot. Circulation: Cardiovascular Genetics, 2013, 6, 528-530.	5.1	5
126	Sudden cardiac death rates in an Australian population: a data linkage study. Australian Health Review, 2015, 39, 561.	0.5	5

#	Article	IF	Citations
127	Harmonizing the Collection of Clinical Data on Genetic Testing Requisition Forms to Enhance Variant Interpretation in Hypertrophic Cardiomyopathy (HCM). Journal of Molecular Diagnostics, 2021, 23, 589-598.	1.2	5
128	NOS1AP Polymorphisms Modify QTc Interval Duration But Not Cardiac Arrest Risk in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2015, 26, 1346-1351.	0.8	4
129	Sudden deaths during the largest community running event in Australia: A 25-year review. International Journal of Cardiology, 2016, 203, 1029-1031.	0.8	4
130	A clinical approach to genetic testing for non-specialists. BMJ: British Medical Journal, 2017, 358, j4101.	2.4	4
131	Daily Step Count as a Simple Marker of Disease Severity in Hypertrophic Cardiomyopathy. Heart Lung and Circulation, 2018, 27, 752-755.	0.2	4
132	Evaluating a custom-designed aid to improve communication of genetic results in families with hypertrophic cardiomyopathy: study protocol for a randomised controlled trial. BMJ Open, 2019, 9, e026627.	0.8	4
133	Making the case for cascade screening among families with inherited heart disease. Heart Rhythm, 2020, 17, 113-114.	0.3	4
134	Prevalence of Anderson-Fabry disease in a cohort with unexplained late gadolinium enhancement on cardiac MRI. International Journal of Cardiology, 2020, 304, 122-124.	0.8	4
135	Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. Internal Medicine Journal, 2021, 51, 769-779.	0.5	4
136	Patients With Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement. Heart Lung and Circulation, 2020, 29, e85-e87.	0.2	4
137	Reply. Journal of the American College of Cardiology, 2015, 66, 1846-1847.	1.2	3
138	Family Matters. Circulation Genomic and Precision Medicine, 2018, 11, e002112.	1.6	3
139	Response by Ingles and Semsarian to Letter Regarding Article, â€œConcealed Arrhythmogenic Right Ventricular Cardiomyopathy in Sudden Unexplained Cardiac Death Eventsâ€• Circulation Genomic and Precision Medicine, 2019, 12, e002475.	1.6	3
140	Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective. American Journal of Preventive Cardiology, 2021, 6, 100151.	1.3	3
141	Sudden death in athletes: Preventable or inevitable?. Heart Rhythm, 2014, 11, 1682-1683.	0.3	2
142	Preventing sudden cardiac death in athletes. BMJ, The, 2016, 353, i1270.	3.0	2
143	NON-FAMILIAL HYPERTROPHIC CARDIOMYOPATHY: PREVALENCE, NATURAL HISTORY AND CLINICAL IMPLICATIONS. Journal of the American College of Cardiology, 2017, 69, 839.	1.2	2
144	Routinely collected health data to study inherited heart disease: a systematic review (2000â€“2016). Open Heart, 2017, 4, e000686.	0.9	2

#	Article	IF	Citations
145	An Unexpected FLNC Phenotype. Mayo Clinic Proceedings, 2019, 94, 751-753.	1.4	2
146	What do we do and how do we do it? Assessing genetic counselling in the modern era. European Journal of Human Genetics, 2020, 28, 1137-1138.	1.4	2
147	Investigation of current models of care for genetic heart disease in Australia: A national clinical audit. International Journal of Cardiology, 2021, 330, 128-134.	0.8	2
148	Mutation analysis of the natriuretic peptide precursor B (NPPB) gene in patients with hypertrophic cardiomyopathy. DNA Sequence, 2006, 17, 392-395.	0.7	1
149	Erratum to â€œGuidelines for Genetic Testing of Inherited Cardiac Disordersâ€•[Heart Lung Circ. 20 (2011) 681â€“687]. Heart Lung and Circulation, 2012, 21, 57.	0.2	1
150	Letter by Semsarian and Ingles Regarding Article, â€œA Randomized Trial of Social Media From Circulation â€• Circulation, 2015, 131, e394.	1.6	1
151	Genetics of HCM and Role of Genetic Testing. , 2015, , 77-84.		1
152	The social gradient of taking a family history. European Journal of Cardiovascular Nursing, 2015, 14, 6-7.	0.4	1
153	Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. American Heart Journal, 2019, 214, 28-35.	1.2	1
154	Genetics of HCM and Role of Genetic Testing. , 2019, , 83-91.		1
155	Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations. PLoS ONE, 2020, 15, e0236814.	1.1	1
156	What Is the Risk of Sudden Cardiac Arrest in Inherited Cardiac Conditions?. Journal of the American College of Cardiology, 2020, 75, 2708-2710.	1.2	1
157	Sudden Cardiac Arrest in the Paediatric Population. , 2022, 1, 45-59.		1
158	Abstract 11709: The Impact of Hypertension on Disease Expression in Hypertrophic Cardiomyopathy. Circulation, 2021, 144, .	1.6	1
159	Prevalence of Coronary Artery Anomalies in Young and Middle-Aged Sudden Cardiac Death Victims (from a Prospective State-Wide Registry). American Journal of Cardiology, 2022, , .	0.7	1
160	Editorial commentary: Genetic contributions to cardiovascular disease: The blurred lines between monogenic and polygenic traits. Trends in Cardiovascular Medicine, 2017, 27, 405-407.	2.3	0
161	Genetic Testing. , 2018, , 668-673.		0
162	Response to Brodehl et al.. Genetics in Medicine, 2019, 21, 1248-1249.	1.1	0

#	Article	IF	Citations
163	The formation of a cardiac arrest registry in Australia [End unexplained cardiac death (EndUCP) registry]. Pathology, 2021, 53, S7.	0.3	0
164	Inherited cardiomyopathies. , 2021, , 277-290.		0
165	Genetic Testing. , 2014, , 685-690.		0
166	Clinical Genetics. , 2016, , 25-47.		0
167	Clinical Genetics. , 2020, , 27-50.		0
168	Need for Inclusive Genomic Research. Circulation Genomic and Precision Medicine, 2022, , CIRCGEN122003736.	1.6	0